Hyderabad-based clinical-stage biopharma company Suven Life Sciences is heading to the BIO International Convention 2026, aiming to position its differentiated Central Nervous System (CNS) pipeline in front of global pharma and biotech leaders.
The event runs from June 22–25, 2026, in San Diego, USA, and is widely regarded as one of the industry’s largest partnering conferences.
At the event, Suven will present its portfolio of late-stage and clinical CNS candidates targeting high-unmet-need conditions including agitation in Alzheimer’s dementia, major depressive disorder, narcolepsy, and cognitive impairment in Parkinson’s disease.
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players.
Suven’s delegation will be led by senior leadership and R&D heads, including Venkat Jasti, Chairman and Managing Director, Ramakrishna Nirogi, President and Chief Scientific Officer, Anil Shinde, Vice President, Drug Chemistry, Pradeep Jayarajan, Vice President, Drug Biology.
Chairman and Managing Director Venkat Jasti said: "BIO-2026 offers a valuable opportunity to highlight the meaningful advancements across our clinical pipeline and connect with potential partners who share our dedication to addressing unmet needs in CNS disorders.
"The positive Phase 2b results for Ropanicant in major depressive disorder, promising and favaurble Phase-1 data for SUVN-I6107, continued progress of our Phase-3 programs, Masupirdine for agitation in dementia of Alzheimer's type and Samelisant (AWAKE study) for narcolepsy, underscore the depth and maturity of our portfolio.
"We look forward to exploring strategic partnering and collaboration opportunities that can help accelerate the development and commercialization of these assets,” said Mr. Venkat Jasti, Chairman and Managing Director of Suven Life Sciences.
The company’s strategy at BIO-2026 is clear: convert clinical momentum into global partnerships that can accelerate late-stage development and commercialization across its CNS portfolio.
_256_275.jpeg)
.jpeg)
